STCube (United States)
The U.S. arm of Korean immuno-oncology company STCube, based in Gaithersburg, Maryland, supporting development of the anti-BTN1A1 antibody nelmastobart.
Last updated September 27, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
STCube (United States) is the U.S.-based entity of STCube, Inc. (에스티큐브), a Korean immuno-oncology company listed on the KOSDAQ under ticker 052020. According to Wikidata, the U.S. entity is a company located in Gaithersburg, Maryland. It operates as part of the STCube group, whose parent company is headquartered in Seoul, South Korea, and whose corporate website is stcube.com. The STCube group is focused on precision-medicine-based immuno-oncology. Its lead program is nelmastobart (Nelmastobart), described by the company as the world's first anti-BTN1A1 immune checkpoint inhibitor. BTN1A1 is a novel immune-oncology target that STCube says is expressed mutually exclusively with PD-L1 and is highly expressed in chemotherapy-resistant and resistant cancer cells. The company states that nelmastobart has shown a high level of safety and tolerability with long-term dosing and promising anti-cancer effects in difficult-to-treat cancers. STCube reports that it has completed a successful Phase 1 trial of nelmastobart, confirming its safety and efficacy, and that it has established global networks including with the U.S. MD Anderson Cancer Center. It is pursuing biomarker-driven clinical trials to increase the probability of clinical success. Recent company news highlighted in its press section includes a Phase 2 non-small cell lung cancer trial showing an objective response rate (ORR) of 26% and a disease control rate (DCR) of 87% in pre-selected patients. The U.S. entity in Gaithersburg likely serves as a clinical, regulatory, and business-development foothold for STCube's U.S. operations, consistent with the group's strategy of collaborating with leading research institutions and building strategic partnerships with multinational pharmaceutical companies. The parent company was founded on August 16, 1989, and listed on KOSDAQ on July 5, 2001. Its representative director is Hyun Jin Jung (정현진). The parent's headquarters is at Trade Tower, 511 Yeongdong-daero, Gangnam-gu, Seoul, South Korea.
History
STCube, Inc. (에스티큐브) was founded on August 16, 1989, and listed on the KOSDAQ on July 5, 2001, under ticker 052020. The company is headquartered in Seoul, South Korea, at Trade Tower, 511 Yeongdong-daero, Gangnam-gu. Its representative director is Hyun Jin Jung (정현진). STCube has evolved into a precision-medicine-based immuno-oncology company. Its core focus is the development of first-in-class immuno-oncology therapeutics targeting novel immune checkpoints. The company's lead asset is nelmastobart, described as the world's first anti-BTN1A1 antibody. BTN1A1 is a novel immune-oncology target that STCube says is expressed mutually exclusively with PD-L1 and is highly expressed in chemotherapy-resistant and resistant cancer cells. According to the company, nelmastobart has completed a successful Phase 1 clinical trial, confirming its safety and efficacy. The company emphasizes that nelmastobart has demonstrated a high level of safety and tolerability with long-term dosing, and promising anti-cancer effects in difficult-to-treat cancers with limited treatment options. STCube is conducting biomarker-driven clinical trials to increase the probability of clinical success and has established global networks including with the U.S. MD Anderson Cancer Center. The U.S. entity, STCube (United States), is based in Gaithersburg, Maryland, according to Wikidata. This location places it within the U.S. biotech corridor near Washington, D.C., and the National Institutes of Health, which is consistent with a company engaged in clinical development and regulatory activities in the United States. The U.S. arm likely supports the parent company's U.S. clinical trials, regulatory interactions, and business development efforts, including strategic partnerships with multinational pharmaceutical companies. STCube's website highlights its pipeline, research achievements, and investor relations information. Recent news on the site includes a Phase 2 non-small cell lung cancer trial showing an objective response rate (ORR) of 26% and a disease control rate (DCR) of 87% in pre-selected patients, indicating the company's ongoing clinical progress.
Products and positioning
First-in-class immuno-oncology company targeting novel immune checkpoints, with a focus on BTN1A1 and precision medicine.
Nelmastobart
First-in-class anti-BTN1A1 immune checkpoint inhibitor for immuno-oncology.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/stcube-united-states · Editorial policy · How profiles are compiled